S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levels
Send us a text Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversations to consider the goals for a therapy that, in Ian's words, "treats the patient and not the NASH." Ian Rowe and colleagues have created a model to assess the tradeoff of liver risk reduction vs. CVD risk reduction at different levels of fibrosis and age. The model suggests that for F2 and F3 patients, the cardiovascular profile...
3 Apr 202113min
S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?
Send us a text Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" means in the context of patient diagnosis and whether "less expensive" is always more efficient. In this conversation, he questions whether positioning a second blood-based test between FIB-4 and FibroScan improves cost-effectiveness or, simple diagnosis. One Spoiler Alert: The Leeds data suggests...
3 Apr 202120min
S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithms
Send us a text Ian Rowe joins the Surfers to discuss more detailed findings from the on-going analyses he and Richard Parker are conducting on abnormal liver tests among patients in Leeds, UK. In this episode, Ian discusses three specific findings that seem paradoxical but make complete sense. As Stephen points out several time over the course of the episode, this work demonstrates how complicated and challenging it it to find the fastest, most streamlined way to get each patient to the righ...
1 Apr 202158min
S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market
Send us a text The final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents. In different ways, Mazen Noureddin and each Surfer discuss how cost-effective patient treatment might actually provide the right medicine for the right patient all along the therapeutic path. What makes NASH a little different from other diseases? Because the liver can heal itself, doctors will need t...
28 Mars 202116min
S2-E16.2 - Future Directions for NASH Cost-Effectiveness Research
Send us a text Mazen Noureddin and Stephen Harrison discuss future directions cost-effectiveness research in and outside the U.S. might take, while the Surfers consider the implications. In response to questions from Roger Green and Stephen Harrison, this conversation starts by exploring where cost-effectiveness research might head next. Louise Campbell provides context from other recent studies and Stephen asks about the impact of expanding these models to encompass costs of hepatocellular ...
27 Mars 202114min
S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has Evolved
Send us a text Mazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, and what he has found, while the Surfers comment on the value of this pivotal work. After Mazen discusses how he became engaged in studying cost effectiveness in screening diabetes patients for NASH, he offers a 30,000-foot view of his findings and shares thoughts on what he plans to study next. Stephen Harrison and Louise Campb...
27 Mars 202117min
S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment
Send us a text Mazen Noureddin joins the Surfers to discuss his work determining cost effectiveness of Non-Invasive Testing in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues. Dr. Noureddin starts the discussion by providing a history of cost-effectiveness research in NASH and NAFLD. At a population level, biopsy turns out never to be cost-effective while less expensive tests almost always are. As the group brainstormed implica...
25 Mars 202154min
S2-E15 — Wrapping Up NASH-TAG 2021
Send us a text Surfing the NASH Tsunami closes the book on NASH-TAG 2021 by considering highlights and major themes of the conference. The conversation focuses on the dramatic increase in disease knowledge and drug development over the past year and highlights some specific papers and ideas. A thoughtful, energetic conclusion to a meeting that left much to think about and many reasons to be excited. NASH-TAG co-director Vlad Ratziu and Global Liver Institute President/CEO Donna Cryer join th...
18 Mars 202152min
